MX2019001202A - Compuesto que inhibe la formacion de complejo de c-myc/max/adn. - Google Patents

Compuesto que inhibe la formacion de complejo de c-myc/max/adn.

Info

Publication number
MX2019001202A
MX2019001202A MX2019001202A MX2019001202A MX2019001202A MX 2019001202 A MX2019001202 A MX 2019001202A MX 2019001202 A MX2019001202 A MX 2019001202A MX 2019001202 A MX2019001202 A MX 2019001202A MX 2019001202 A MX2019001202 A MX 2019001202A
Authority
MX
Mexico
Prior art keywords
myc
max
dna complex
inhibiting formation
compound inhibiting
Prior art date
Application number
MX2019001202A
Other languages
English (en)
Inventor
Jung Lim Hwan
Chae Jeong Kyung
Jun Park Seong
Kyung Seo Ho
Ohk Ahn Kyung
Jin Lee Sang
Sook Lee Eun
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Priority claimed from PCT/KR2017/008020 external-priority patent/WO2018021810A1/ko
Publication of MX2019001202A publication Critical patent/MX2019001202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona un compuesto novedoso que tiene una cierta estructura quimica con la actividad de inhibicion de la formacion de un complejo de c-Myc/Max/ADN, o una sal farmaceuticamente aceptable del mismo.
MX2019001202A 2016-07-29 2017-07-25 Compuesto que inhibe la formacion de complejo de c-myc/max/adn. MX2019001202A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160097429 2016-07-29
KR1020170093661A KR101879992B1 (ko) 2016-07-29 2017-07-24 c-Myc/Max/DNA 복합체 형성을 억제하는 화합물
PCT/KR2017/008020 WO2018021810A1 (ko) 2016-07-29 2017-07-25 c-Myc/Max/DNA 복합체 형성을 억제하는 화합물

Publications (1)

Publication Number Publication Date
MX2019001202A true MX2019001202A (es) 2019-09-04

Family

ID=61203724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001202A MX2019001202A (es) 2016-07-29 2017-07-25 Compuesto que inhibe la formacion de complejo de c-myc/max/adn.

Country Status (8)

Country Link
EP (1) EP3495350B1 (es)
KR (1) KR101879992B1 (es)
CN (1) CN109715607B (es)
AU (1) AU2017304434B2 (es)
BR (1) BR112019001805A2 (es)
CA (1) CA3032270C (es)
MX (1) MX2019001202A (es)
RU (1) RU2727177C1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102532517B1 (ko) * 2021-02-05 2023-05-15 한국화학연구원 신규한 설폰아미드 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1192617A3 (ru) * 1981-01-19 1985-11-15 Дзе Бутс Компани Плс (Фирма) Способ получени хинолонов
FR2781218B1 (fr) * 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
KR100574351B1 (ko) * 2004-05-18 2006-04-27 한국화학연구원 4-퀴놀린온 유도체를 포함하는 농원예용 살균제 조성물
EP2124948B1 (en) * 2007-02-21 2017-07-26 NC bit, Inc. Compositions for treating hyperproliferative vascular disorders and cancers
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
KR101074212B1 (ko) * 2009-05-18 2011-10-14 한국화학연구원 4－퀴놀린온 유도체 화합물을 포함하는 수목용 살충제 조성물 및 이를 이용한 살충방법
KR101335458B1 (ko) * 2011-01-04 2013-12-10 한국화학연구원 백혈병 치료용 약학조성물
EP2917203B1 (en) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
CA2942574A1 (en) 2013-12-11 2015-06-18 The Scripps Research Institute Small molecule c-myc inhibitors
KR20150083353A (ko) * 2014-01-09 2015-07-17 국립암센터 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물

Also Published As

Publication number Publication date
BR112019001805A2 (pt) 2019-05-07
AU2017304434B2 (en) 2020-07-09
EP3495350A1 (en) 2019-06-12
AU2017304434A1 (en) 2019-02-28
RU2727177C1 (ru) 2020-07-21
EP3495350B1 (en) 2021-10-20
CA3032270A1 (en) 2018-02-01
KR20180013739A (ko) 2018-02-07
CA3032270C (en) 2021-02-16
CN109715607B (zh) 2022-07-12
CN109715607A (zh) 2019-05-03
EP3495350A4 (en) 2020-01-08
KR101879992B1 (ko) 2018-07-19

Similar Documents

Publication Publication Date Title
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
PH12017501523A1 (en) Selective bace1 inhibitors
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2018006148A (es) Inhibidores de cxcr2.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
IN2015DN01331A (es)
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
WO2016024289A3 (en) Novel salts of nilotinib and polymorphs thereof
EP3220920A4 (en) Combination therapy effective against microorganisms, including drug resistant microorganisms
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MX2019001202A (es) Compuesto que inhibe la formacion de complejo de c-myc/max/adn.
MX2019002993A (es) Arreglo de microagujas.
WO2017191619A3 (en) A process for the preparation of a salt of sacubitril and valsartan
MX2019005504A (es) Potenciadores de bmp.
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
AR122557A2 (es) Oligonucleótido modificado
EP3902793A4 (en) MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES
GB201914470D0 (en) H.e.r.o iv
PL422738A1 (pl) Mieszanina biobójcza ze szczególnym uwzględnieniem usuwania grzyba z elementów konstrukcyjnych
GB201705502D0 (en) Antimalarial medicine intermediates 2,4-diclorobenzoic acid synthesis
AU2016900693A0 (en) Location controlled gun locks.
AU2016900639A0 (en) Location controlled gun locks.